GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
A Pilot, Phase II, Open-label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults
Sponsor: ViiV Healthcare
Listed as NCT00257621, this PHASE2 trial focuses on HIV Infection and Infection, Human Immunodeficiency Virus I and remains completed. Sponsored by ViiV Healthcare, it has been updated 7 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Jul 2017 [monthly]
Completed PHASE2
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .